ZA200901993B - Novel neutralizing immunogen (NIMIV) of rhinovirus and its use for vaccine applicants - Google Patents

Novel neutralizing immunogen (NIMIV) of rhinovirus and its use for vaccine applicants

Info

Publication number
ZA200901993B
ZA200901993B ZA200901993A ZA200901993A ZA200901993B ZA 200901993 B ZA200901993 B ZA 200901993B ZA 200901993 A ZA200901993 A ZA 200901993A ZA 200901993 A ZA200901993 A ZA 200901993A ZA 200901993 B ZA200901993 B ZA 200901993B
Authority
ZA
South Africa
Prior art keywords
nimiv
rhinovirus
applicants
vaccine
novel neutralizing
Prior art date
Application number
ZA200901993A
Other languages
English (en)
Inventor
Kirill Kalnin
Yanhua Yan
Harold Kleanthous
Original Assignee
Sanofi Pasteur Biologics Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Pasteur Biologics Co filed Critical Sanofi Pasteur Biologics Co
Publication of ZA200901993B publication Critical patent/ZA200901993B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/125—Picornaviridae, e.g. calicivirus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1009—Picornaviridae, e.g. hepatitis A virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6081—Albumin; Keyhole limpet haemocyanin [KLH]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32711—Rhinovirus
    • C12N2770/32722—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32711—Rhinovirus
    • C12N2770/32734—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Pulmonology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
ZA200901993A 2006-09-29 2007-10-01 Novel neutralizing immunogen (NIMIV) of rhinovirus and its use for vaccine applicants ZA200901993B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US84845106P 2006-09-29 2006-09-29

Publications (1)

Publication Number Publication Date
ZA200901993B true ZA200901993B (en) 2010-07-28

Family

ID=39364960

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200901993A ZA200901993B (en) 2006-09-29 2007-10-01 Novel neutralizing immunogen (NIMIV) of rhinovirus and its use for vaccine applicants

Country Status (12)

Country Link
US (2) US8652486B2 (zh)
EP (2) EP2548573A1 (zh)
JP (1) JP2010504759A (zh)
KR (1) KR20090092764A (zh)
CN (1) CN101678095B (zh)
AU (1) AU2007318206A1 (zh)
BR (1) BRPI0719443A2 (zh)
CA (1) CA2664628C (zh)
IL (1) IL197755A (zh)
MX (1) MX2009003301A (zh)
WO (1) WO2008057158A2 (zh)
ZA (1) ZA200901993B (zh)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2007347184A1 (en) * 2006-09-29 2008-08-21 Sanofi Pasteur Biologics Co Recombinant rhinovirus vectors
CN102089003A (zh) * 2008-03-27 2011-06-08 赛诺菲巴斯德生物制剂公司 重组鼻病毒载体
EP2316481A1 (en) * 2009-10-30 2011-05-04 Biomay Ag Pharmaceutical composition for the treatment and prevention of a rhinovirus infection
GB201115910D0 (en) 2011-09-14 2011-10-26 Univ Manchester Peptides
BE1022174B1 (fr) * 2013-03-15 2016-02-24 Glaxosmithkline Biologicals S.A. Vaccin
CA2906909A1 (en) * 2013-03-15 2014-09-18 Biological Mimetics, Inc. Immunogenic human rhinovirus (hrv) composition
EP3307311A4 (en) * 2015-06-15 2019-02-13 Emory University MULTIVALENT ENTEROVIRUS VACCINE COMPOSITIONS AND USES THEREOF
GB201616904D0 (en) 2016-10-05 2016-11-16 Glaxosmithkline Biologicals Sa Vaccine

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0169146A3 (en) 1984-07-20 1988-07-20 Merck & Co. Inc. Monoclonal antibodies directed against the cellular receptor of human rhinovirus
JPS6147191A (ja) * 1984-07-20 1986-03-07 メルク　エンド　カムパニー　インコーポレーテッド ヒト・ライノウイルスｒｎａおよびたんぱく
US5541100A (en) * 1990-09-12 1996-07-30 Rutgers University Chimeric rhinoviruses
US20030138769A1 (en) 2000-08-16 2003-07-24 Birkett Ashley J. Immunogenic HBc chimer particles having enhanced stability
US7361352B2 (en) 2001-08-15 2008-04-22 Acambis, Inc. Influenza immunogen and vaccine
US20040146524A1 (en) 2002-02-21 2004-07-29 Katelynne Lyons Stabilized immunogenic HBc chimer particles
US7429472B2 (en) * 2003-01-31 2008-09-30 Promega Corporation Method of immobilizing a protein or molecule via a mutant dehalogenase that is bound to an immobilized dehalogenase substrate and linked directly or indirectly to the protein or molecule
MX2007003726A (es) * 2004-09-28 2007-06-15 Johnson & Johnson Estabilizaci??n de agentes inmunologicamente activos con adyuvantes de alumbre.
WO2006078648A2 (en) * 2005-01-19 2006-07-27 Donald Danforth Plant Science Center Rhinovirus vaccines

Also Published As

Publication number Publication date
WO2008057158A9 (en) 2008-09-18
AU2007318206A1 (en) 2008-05-15
CN101678095A (zh) 2010-03-24
AU2007318206A2 (en) 2009-06-04
IL197755A0 (en) 2011-08-01
EP2548573A1 (en) 2013-01-23
KR20090092764A (ko) 2009-09-01
US9381237B2 (en) 2016-07-05
EP2066343B1 (en) 2017-06-14
WO2008057158A3 (en) 2008-08-07
US8652486B2 (en) 2014-02-18
BRPI0719443A2 (pt) 2013-12-10
US20100297169A1 (en) 2010-11-25
EP2066343A2 (en) 2009-06-10
MX2009003301A (es) 2009-07-15
CN101678095B (zh) 2013-04-24
CA2664628C (en) 2016-08-09
WO2008057158A2 (en) 2008-05-15
IL197755A (en) 2015-09-24
EP2066343A4 (en) 2010-05-19
US20140161833A1 (en) 2014-06-12
JP2010504759A (ja) 2010-02-18
CA2664628A1 (en) 2008-05-15

Similar Documents

Publication Publication Date Title
HK1249031A1 (zh) 疫苗施用的方法
EP2007284A4 (en) DEVICES AND METHOD FOR TISSUE TREATMENT
IL194820A0 (en) Devices and methods for treatment of tissue
ZA200901993B (en) Novel neutralizing immunogen (NIMIV) of rhinovirus and its use for vaccine applicants
EG27114A (en) Degradable whipstock apparatus and methods of use
EP2068898A4 (en) BONE CEMENT AND APPLICATION METHOD THEREFOR
IL194958A0 (en) Use of arylcarboxylic acid biphenylamides for seed treatment
IL193460A0 (en) Compounds and methods for treatment of stroke
ZA200906126B (en) Use of IL-23 antigonists for treatment of infection
PL2054066T3 (pl) Sposoby leczenia popromiennego zapalenia jelit
EP2007303A4 (en) SYSTEM AND METHOD FOR MICRO-ABLATION OF FABRICS
EP2480159A4 (en) DENTAL INSTRUMENT WITH LIGHTING, COUPLING AND APPLICATION USE
EP2039392A4 (en) DEVICE FOR PHYSIOTHERAPY TREATMENT OF DISEASES OF VARIOUS AITIOLOGIES
EP2207516A4 (en) DEVICE FOR THE TREATMENT OF VAGINAL MYCOSIS
EP2145952A4 (en) PROCESS FOR THE REMOVAL OF BIOLOGICAL TISSUE
GB0625899D0 (en) Apparatus for the cultivation of shellfish
GB0620695D0 (en) Composition and methods for the treatment of nurdegenerative disease
EP2061506A4 (en) VACCINE COMPOSITION AND IMMUNIZATION METHOD
PL117724U1 (pl) Urządzenie do biologicznego oczyszczania ścieków
GB0623740D0 (en) Treatment of disease
HUP0600042A2 (en) New medical use of thiolated pyrimidine-mononucleotides and -nucleosides
RU63676U8 (ru) Устройство для транспортной иммобилизации переломов нижней челюсти
HU0700076V0 (en) Device for covered introduction of scalpels
GB0601035D0 (en) Method of vaccine preparation
GB0622471D0 (en) Use of reversine and analogs for treatment of cancer